Major Rating Factors: Weak overall results on stability tests (0.5 on a scale of 0 to 10) including excessive premium growth. The largest net exposure for one risk is excessive at 19.6% of capital. Good long-term capitalization index (5.0) based on weak current risk adjusted capital (severe loss scenario), although results have slipped from the good range during the last year.
Other Rating Factors: Fair reserve development (3.6) as reserves have generally been sufficient to cover claims. Good overall profitability index (6.4) despite operating losses during 2020 and the first six months of 2022. Good liquidity (6.5) with sufficient resources (cash flows and marketable investments) to handle a spike in claims.
Stability Factors: D - Limited diversification of general business, policy, and/or investment risk. G - Fast asset or premium growth. R - Concerns about the financial strength of its reinsurers. T - Significant trends in critical asset, liability, income or expense items.
Principal Lines of Business: Med mal (98.7%), other (1.3%)
Licensed in: CT, MA, MO, NH, NJ, NY
Principal Investments: Investment grade bonds (88.3%), cash (10.3%), other (1.4%)